Mesenchymal stem cells for the treatment of neurodegenerative disease

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

• 1  Williams JT, Southerland SS, Souza J et al.: Cells isolated from adult human skeletal muscle capable of differentiating into multiple mesodermal phenotypes. Am. Surg.65,22–26 (1999).
  Medline CASGoogle Scholar
• 2  Galmiche MC, Koteliansky VE, Briere J et al.: Stromal cells from human long-term marrow cultures are mesenchymal cells that differentiate following a vascular smooth muscle differentiation pathway. Blood82,66–76 (1993).
  Medline CASGoogle Scholar
• 3  Theise ND, Nimmakayalu M, Gardner R et al.: Liver from bone marrow in humans. Hepatology32,11–16 (2000).
  Medline CASGoogle Scholar
• 4  Theise ND, Badve S, Saxena R et al.: Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation. Hepatology31,235–240 (2000).
  Medline CASGoogle Scholar
• 5  Petersen BE, Bowen WC, Patrene KD et al.: Bone marrow as a potential source of hepatic oval cells. Science284,1168–1170 (1999).
  Medline CASGoogle Scholar
• 6  Lagasse E, Connors H, Al-Dhalimy M et al.: Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat. Med.6,1229–1234 (2000).
  Medline CASGoogle Scholar
• 7  Orlic D, Kajstura J, Chimenti S et al.: Bone marrow cells regenerate infarcted myocardium. Nature410,701–705 (2001).
  Medline CASGoogle Scholar
• 8  Wu GD, Nolta JA, Jin YS et al.: Migration of mesenchymal stem cells to heart allografts during chronic rejection. Transplantation75,679–685 (2003).
  MedlineGoogle Scholar
• 9  Jackson KA, Majka SM, Wang H et al.: Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J. Clin. Invest.107,1395–1402 (2001).
  Medline CASGoogle Scholar
• 10  Zimmet JM, Hare JM: Emerging role for bone marrow derived mesenchymal stem cells in myocardial regenerative therapy. Basic Res. Cardiol.100,471–481 (2005).
  Medline CASGoogle Scholar
• 11  Davidoff AM, Ng CY, Brown P et al.: Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin. Cancer Res.7,2870–2879 (2001).
  Medline CASGoogle Scholar
• 12  Crisa L, Cirulli V, Smith KA et al.: Human cord blood progenitors sustain thymic T-cell development and a novel form of angiogenesis. Blood94,3928–3940 (1999).
  Medline CASGoogle Scholar
• 13  Peichev M, Naiyer AJ, Pereira D et al.: Expression of VEGFR-2 and AC133 by circulating human CD34⁺ cells identifies a population of functional endothelial precursors. Blood95,952–958 (2000).
  Medline CASGoogle Scholar
• 14  Le Blanc K: Mesenchymal stromal cells: tissue repair and immune modulation. Cytotherapy8,559–561 (2006).▪ Discusses mechanisms by which allogenic mesenchymal stem cells (MSCs) shelter themseleves from the host immune system.
  Medline CASGoogle Scholar
• 15  Laflamme MA, Murry CE: Regenerating the heart. Nat. Biotechnol.23,845–856 (2005).
  Medline CASGoogle Scholar
• 16  Chen J, Li Y, Katakowski M et al.: Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J. Neurosci. Res.73,778–786 (2003).
  Medline CASGoogle Scholar
• 17  Li Y, Chen J, Zhang CL et al.: Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia49,407–417 (2005).
  MedlineGoogle Scholar
• 18  Murphy JM, Fink DJ, Hunziker EB et al.: Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum.48,3464–3474 (2003).
  MedlineGoogle Scholar
• 19  Rosova I, Dao M, Capoccia B et al.: Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. Stem Cells26(8),2173–2182 (2008).
  Medline CASGoogle Scholar
• 20  Kinnaird T, Stabile E, Burnett MS et al.: Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ. Res.94,678–685 (2004).
  Medline CASGoogle Scholar
• 21  Gnecchi M, He H, Noiseux N et al.: Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J.20,661–669 (2006).
  Medline CASGoogle Scholar
• 22  Meyerrose T, De Ugarte D, Hofling A et al.: In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells25,220–227 (2007).
  Medline CASGoogle Scholar
• 23  Meyerrose TE, Roberts M, Ohlemiller KK et al.: Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. Stem Cells26,1713–1722 (2008).
  Medline CASGoogle Scholar
• 24  Bauer G, Dao MA, Case SS et al.: In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors. Mol. Ther.16,1308–1315 (2008).▪▪ Represents a decade-long biosafety study that confirmed the safety of genetically engineered human MSCs, tested in vivo.
  Medline CASGoogle Scholar
• 25  Dao MA, Pepper KA, Nolta JA: Long-term cytokine production from engineered primary human stromal cells influences human hematopoiesis in an in vivo xenograft model. Stem Cells15,443–454 (1997).▪ One of the earliest reports of the durability and safety of systemic production of growth factors from genetically engineered human MSCs.
  Medline CASGoogle Scholar
• 26  Nolta J: Genetic Engineering of Mesenchymal Stem Cells. Springer, Dordrecht, The Netherlands (2006).
  Google Scholar
• 27  Capoccia BJ, Robson DL, Levac KD et al.: Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood113,5340–5351 (2009).
  Medline CASGoogle Scholar
• 28  Danielyan L, Schafer R, von Ameln-Mayerhofer A et al.: Intranasal delivery of cells to the brain. Eur. J. Cell Biol.88,315–324 (2009).
  Medline CASGoogle Scholar
• 29  Crigler L, Robey RC, Asawachaicharn A et al.: Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp. Neurol.198,54–64 (2006).▪▪ Comprehensive examination of the effects of MSCs on neurons.
  Medline CASGoogle Scholar
• 30  Munoz JR, Stoutenger BR, Robinson AP et al.: Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc. Natl Acad. Sci. USA102,18171–18176 (2005).
  Medline CASGoogle Scholar
• 31  Kassis I, Grigoriadis N, Gowda-Kurkalli B et al.: Neuroprotection and immunomodulation with mesenchymal stem cells in chronic experimental autoimmune encephalomyelitis. Arch. Neurol.65,753–761 (2008).▪ In vivo MSC-based neuroprotection model.
  MedlineGoogle Scholar
• 32  Tolar J, Nauta AJ, Osborn MJ et al.: Sarcoma derived from cultured mesenchymal stem cells. Stem Cells25(2),371–379 (2007).
  Medline CASGoogle Scholar
• 33  Kidd S, Spaeth E, Dembinski JL et al.: Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells27,2614–2623 (2009).
  Medline CASGoogle Scholar
• 34  Kidd S, Spaeth E, Klopp A et al.: The (in) auspicious role of mesenchymal stromal cells in cancer: be it friend or foe. Cytotherapy10,657–667 (2008).
  Medline CASGoogle Scholar
• 35  Kim HJ, McMillan E, Han F et al.: Regionally specified human neural progenitor cells derived from the mesencephalon and forebrain undergo increased neurogenesis following overexpression of ASCL1. Stem Cells27,390–398 (2009).
  Medline CASGoogle Scholar
• 36  Sharp J, Keirstead HS: Stem cell-based cell replacement strategies for the central nervous system. Neurosci. Lett.456,107–111 (2009).
  Medline CASGoogle Scholar
• 37  Hardy SA, Maltman DJ, Przyborski SA: Mesenchymal stem cells as mediators of neural differentiation. Curr. Stem Cell Res. Ther.3,43–52 (2008).▪▪ Effects of MSCs on differentiation from neural precursors.
  Medline CASGoogle Scholar
• 38  Rechavi O, Goldstein I, Kloog Y: Intercellular exchange of proteins: the immune cell habit of sharing. FEBS Lett.583,1792–1799 (2009).
  Medline CASGoogle Scholar
• 39  Spees JL, Olson SD, Whitney MJ et al.: Mitochondrial transfer between cells can rescue aerobic respiration. Proc. Natl Acad. Sci. USA103,1283–1288 (2006).▪▪ An important paradigm-shifting study that definitively demonstrated that human MSCs can transfer components as large as mitochondria to other, damaged cells, through direct cell-to-cell trafficking.
  Medline CASGoogle Scholar
• 40  Wilkins A, Kemp K, Ginty M et al.: Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res. (2009 (Epub ahead of print).▪ Secretion of brain-derived neurotrophic factor (BDNF) from MSCs promotes neuronal survival.
  Google Scholar
• 41  Endo Y, Beauchamp E, Woods D et al.: Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in Ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Mol. Cell Biol.28,2368–2379 (2008).
  Medline CASGoogle Scholar
• 42  Etheridge SL, Spencer GJ, Heath DJ et al.: Expression profiling and functional analysis of wnt signaling mechanisms in mesenchymal stem cells. Stem Cells22,849–860 (2004).
  Medline CASGoogle Scholar
• 43  Gregory CA, Singh H, Perry AS et al.: The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow. J. Biol. Chem.278,28067–28078 (2003).
  Medline CASGoogle Scholar
• 44  Allen J, Chilton JK: The specific targeting of guidance receptors within neurons: who directs the directors? Dev. Biol.327,4–11 (2009).
  Medline CASGoogle Scholar
• 45  Aizman I, Tate CC, McGrogan M et al.: Extracellular matrix produced by bone marrow stromal cells and by their derivative, SB623 cells, supports neural cell growth. J. Neurosci. Res.87,3198–3206 (2009).
  Medline CASGoogle Scholar
• 46  Croft AP, Przyborski SA: Mesenchymal stem cells expressing neural antigens instruct a neurogenic cell fate on neural stem cells. Exp. Neurol.216,329–341 (2009).
  Medline CASGoogle Scholar
• 47  Boudreau RL, McBride JL, Martins I et al.: Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington’s disease mice. Mol. Ther.17,1053–1063 (2009).
  Medline CASGoogle Scholar
• 48  Harper SQ, Staber PD, He X et al.: RNA interference improves motor and neuropathological abnormalities in a Huntington’s disease mouse model. Proc. Natl Acad. Sci. USA102,5820–5825 (2005).
  Medline CASGoogle Scholar
• 49  DiFiglia M, Sena-Esteves M, Chase K et al.: Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl Acad. Sci. USA104,17204–17209 (2007).
  Medline CASGoogle Scholar
• 50  Wang YL, Liu W, Wada E et al.: Clinico-pathological rescue of a model mouse of Huntington’s disease by siRNA. Neurosci. Res.53,241–249 (2005).
  Medline CASGoogle Scholar
• 51  Lombardi MS, Jaspers L, Spronkmans C et al.: A majority of Huntington’s disease patients may be treatable by individualized allele-specific RNA interference. Exp. Neurol.217,312–319 (2009).
  Medline CASGoogle Scholar
• 52  Pfister EL, Kennington L, Straubhaar J et al.: Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington’s disease patients. Curr. Biol.19,774–778 (2009).
  Medline CASGoogle Scholar
• 53  Zhang Y, Engelman J, Friedlander RM: Allele-specific silencing of mutant Huntington’s disease gene. J. Neurochem.108,82–90 (2009).
  Medline CASGoogle Scholar
• 54  Lescaudron L, Unni D, Dunbar GL: Autologous adult bone marrow stem cell transplantation in an animal model of Huntington’s disease: behavioral and morphological outcomes. Int. J. Neurosci.113,945–956 (2003).
  MedlineGoogle Scholar
• 55  Bantubungi K, Blum D, Cuvelier L et al.: Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington’s disease. Mol. Cell. Neurosci.37,454–470 (2008).
  Medline CASGoogle Scholar
• 56  Amin EM, Reza BA, Morteza BR et al.: Microanatomical evidences for potential of mesenchymal stem cells in amelioration of striatal degeneration. Neurol. Res.30,1086–1090 (2008).▪ MSCs could delay striatal decline in a Huntingdon’s disease (HD) model.
  MedlineGoogle Scholar
• 57  Watts C, McNamara IR, Dunnett SB: Volume and differentiation of striatal grafts in rats: relationship to the number of cells implanted. Cell Transplant.9,65–72 (2000).
  Medline CASGoogle Scholar
• 58  Delcroix GJ, Jacquart M, Lemaire L et al.: Mesenchymal and neural stem cells labeled with HEDP-coated SPIO nanoparticles: in vitro characterization and migration potential in rat brain. Brain Res.1255,18–31 (2009).
  Medline CASGoogle Scholar
• 59  Sadan O, Shemesh N, Barzilay R et al.: Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging. Stem Cells26,2542–2551 (2008).▪▪ Demonstrates that MSCs migrated specifically to the region of striatal damage after infusion into the brain in an HD rat model.
  Medline CASGoogle Scholar
• 60  Sadan O, Shemesh N, Cohen Y et al.: Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases. Isr. Med. Assoc. J.11,201–204 (2009).
  MedlineGoogle Scholar
• 61  Bachoud-Levi AC, Gaura V, Brugieres P et al.: Effect of fetal neural transplants in patients with Huntington’s disease 6 years after surgery: a long-term follow-up study. Lancet Neurol.5,303–309 (2006).
  MedlineGoogle Scholar
• 62  Gaura V, Bachoud-Levi AC, Ribeiro MJ et al.: Striatal neural grafting improves cortical metabolism in Huntington’s disease patients. Brain127,65–72 (2004).
  MedlineGoogle Scholar
• 63  Canals JM, Pineda JR, Torres-Peraza JF et al.: Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington’s disease. J. Neurosci.24,7727–7739 (2004).
  Medline CASGoogle Scholar
• 64  Her LS, Goldstein LS: Enhanced sensitivity of striatal neurons to axonal transport defects induced by mutant huntingtin. J. Neurosci.28,13662–13672 (2008).
  Medline CASGoogle Scholar
• 65  Wu LL, Fan Y, Li S et al.: Huntingtin associated protein-1 interacts with proBDNF and mediates its transport and release. J. Biol. Chem.285(8),5614–5623 (2009).
  MedlineGoogle Scholar
• 66  Gharami K, Xie Y, An JJ et al.: Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington’s disease phenotypes in mice. J. Neurochem.105,369–379 (2008).
  Medline CASGoogle Scholar
• 67  Zuccato C, Cattaneo E: Brain-derived neurotrophic factor in neurodegenerative diseases. Nature Rev.5,311–322 (2009).▪ Highlights the importance of BDNF in ameliorating the neurodegeneration that occurs in HD.
  CASGoogle Scholar
• 68  Alberch J, Perez-Navarro E, Canals JM: Neurotrophic factors in Huntington’s disease. Prog. Brain Res.146,195–229 (2004).
  Medline CASGoogle Scholar
• 69  Dey ND, Bombard MC, Roland BP et al.: Genetically-engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington’s disease. Behav. Brain Res.214(2),193–200 (2010).▪▪ Both BDNF-modified and non-modified MSCs had significant effects in reducing the behavioral defects in an HD mouse model.
  Medline CASGoogle Scholar
• 70  Nolta JA, Dao MA, Wells S et al.: Transduction of pluripotent human hematopoietic stem cells demonstrated by clonal analysis after engraftment in immune-deficient mice. Proc. Natl Acad. Sci. USA93,2414–2419 (1996).
  Medline CASGoogle Scholar
• 71  Nolta JA, Kohn DB: Comparison of the effects of growth factors on retroviral vector-mediated gene transfer and the proliferative status of human hematopoietic progenitor cells. Hum. Gene Ther.1,257–268 (1990).
  Medline CASGoogle Scholar
• 72  Tsark E, Dao M, Wang X et al.: IL-7 enhances the responsiveness of human T cells that develop in the bone marrow of athymic mice. J. Immunol.166,170–181 (2001).
  Medline CASGoogle Scholar
• 73  Wang X, Ge S, McNamara G et al.: Albumin expressing hepatocyte-like cells develop in the livers of immune-deficient mice transmitted with highly purified human hematopoietic stem cells. Blood101(10),4201–4208 (2003).
  Medline CASGoogle Scholar
• 74  Nolta JA, Hanley MB, Kohn DB: Sustained human hematopoiesis in immunodeficient mice by cotransplantation of marrow stroma expressing human interleukin-3: analysis of gene transduction of long-lived progenitors. Blood83,3041–3051 (1994).
  Medline CASGoogle Scholar
• 75  Meyerrose T, Rosova I, Dao M et al.: Establishment and Transduction of Primary Human Stromal/ Mesenchymal Stem Cell Monolayers. Kluwer Academic Publishers, Dordrecht, The Netherlands (2006).
  Google Scholar
• 76  Vucic S, Kiernan MC: Pathophysiology of neurodegeneration in familial amyotrophic lateral sclerosis. Curr. Mol. Med.9,255–272 (2009).
  Medline CASGoogle Scholar
• 77  Maxwell MM: RNAi applications in therapy development for neurodegenerative disease. Curr. Pharm. Des.15,3977–3991 (2009).
  Medline CASGoogle Scholar
• 78  Kim SU, de Vellis J: Stem cell-based cell therapy in neurological diseases: a review. J. Neurosci. Res.87,2183–2200 (2009).
  Medline CASGoogle Scholar
• 79  Ionov ID: Survey of ALS-associated factors potentially promoting Ca²⁺ overload of motor neurons. Amyotroph. Lateral Scler.8,260–265 (2007).
  Medline CASGoogle Scholar
• 80  Julien JP, Kriz J: Transgenic mouse models of amyotrophic lateral sclerosis. Biochim. Biophys. Acta1762,1013–1024 (2006).
  Medline CASGoogle Scholar
• 81  Bruijn LI, Miller TM, Cleveland DW: Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci.27,723–749 (2004).
  Medline CASGoogle Scholar
• 82  Zhao CP, Zhang C, Zhou SN et al.: Human mesenchymal stromal cells ameliorate the phenotype of SOD1-G93A ALS mice. Cytotherapy9,414–426 (2007).▪▪ Demonstrates the positive effects of MSCs in an amyotrophic lateral sclerosis (ALS) model.
  Medline CASGoogle Scholar
• 83  Vercelli A, Mereuta OM, Garbossa D et al.: Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis.31,395–405 (2008).▪▪ Demonstrates the positive effects of MSCs in an in vivo ALS model.
  Medline CASGoogle Scholar
• 84  Morita E, Watanabe Y, Ishimoto M et al.: A novel cell transplantation protocol and its application to an ALS mouse model. Exp. Neurol.213,431–438 (2008).
  Medline CASGoogle Scholar
• 85  Fischer LR, Culver DG, Tennant P et al.: Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol.185,232–240 (2004).
  MedlineGoogle Scholar
• 86  Klein SM, Behrstock S, McHugh J et al.: GDNF delivery using human neural progenitor cells in a rat model of ALS. Hum. Gene Ther.16,509–521 (2005).
  Medline CASGoogle Scholar
• 87  Suzuki M, McHugh J, Tork C et al.: GDNF secreting human neural progenitor cells protect dying motor neurons, but not their projection to muscle, in a rat model of familial ALS. PLoS ONE2,e689 (2007).▪▪ Human GDNF-expressing MSCs had significant effects on ameliorating ALS symptoms.
  MedlineGoogle Scholar
• 88  Suzuki M, McHugh J, Tork C et al.: Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol. Ther.16,2002–2010 (2008).
  Medline CASGoogle Scholar
• 89  Funakoshi H, Ohya W, Kadoyama K et al.: [ALS and neurotrophic factors – HGF as a novel neurotrophic and neuroregenerative factor]. Brain Nerve59,1195–1202 (2007).
  Medline CASGoogle Scholar
• 90  Kadoyama K, Funakoshi H, Ohya W et al.: Hepatocyte growth factor (HGF) attenuates gliosis and motoneuronal degeneration in the brainstem motor nuclei of a transgenic mouse model of ALS. Neurosci. Res.59,446–456 (2007).
  Medline CASGoogle Scholar
• 91  Donsante A, Miller DG, Li Y et al.: AAV vector integration sites in mouse hepatocellular carcinoma. Science317,477 (2007).
  Medline CASGoogle Scholar
• 92  Nagano I, Ilieva H, Shiote M et al.: Therapeutic benefit of intrathecal injection of insulin-like growth factor-1 in a mouse model of amyotrophic lateral sclerosis. J. Neurol. Sci.235,61–68 (2005).
  Medline CASGoogle Scholar
• 93  Nagano I, Shiote M, Murakami T et al.: Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis. Neurosci. Res.27,768–772 (2005).
  CASGoogle Scholar
• 94  Mazzini L, Ferrero I, Luparello V et al.: Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a Phase I clinical trial. Exp. Neurol.223(1),229–237 (2009).▪▪ MSCs were safely infused into the CNS of ten ALS patients in a Phase I clinical trial.
  MedlineGoogle Scholar
• 95  Greene P: Cell-based therapies in Parkinson’s disease. Curr. Neurol. Neurosci. Rep.9,292–297 (2009).
  MedlineGoogle Scholar
• 96  Jenner P: Functional models of Parkinson’s disease: a valuable tool in the development of novel therapies. Ann. Neurol.64(Suppl. 2),S16–S29 (2008).
  Medline CASGoogle Scholar
• 97  Jin GZ, Cho SJ, Choi EG et al.: Rat mesenchymal stem cells increase tyrosine hydroxylase expression and dopamine content in ventral mesencephalic cells in vitro. Cell Biol. Int.32,1433–1438 (2008).
  Medline CASGoogle Scholar
• 98  Bouchez G, Sensebe L, Vourc’h P et al.: Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson’s disease. Neurochem. Int.52,1332–1342 (2008).
  Medline CASGoogle Scholar
• 99  Sadan O, Bahat-Stromza M, Barhum Y et al.: Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev.18,1179–1190 (2009).
  Medline CASGoogle Scholar
• 100  Peterson AL, Nutt JG: Treatment of Parkinson’s disease with trophic factors. Neurotherapeutics5,270–280 (2008).
  Medline CASGoogle Scholar
• 101  Manfredsson FP, Okun MS, Mandel RJ: Gene therapy for neurological disorders: challenges and future prospects for the use of growth factors for the treatment of Parkinson’s disease. Curr. Gene Ther.9,375–388 (2009).
  Medline CASGoogle Scholar
• 102  Ramaswamy S, Soderstrom KE, Kordower JH: Trophic factors therapy in Parkinson’s disease. Prog. Brain Res.175,201–216 (2009).
  Medline CASGoogle Scholar
• 103  Li JY, Englund E, Holton JL et al.: Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat. Med.14,501–503 (2008).
  Medline CASGoogle Scholar
• 104  Mazzini L, Fagioli F, Boccaletti R et al.: Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. Amyotroph. Lateral Scler. Other Motor Neuron Disord.4,158–161 (2003).
  MedlineGoogle Scholar
• 105  Karussis D, Kassis I, Kurkalli BG et al.: Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J. Neurol. Sci.265,131–135 (2008).
  Medline CASGoogle Scholar
• 106  Mancardi G, Saccardi R: Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol.7,626–636 (2008).
  MedlineGoogle Scholar
• 107  Saccardi R, Kozak T, Bocelli-Tyndall C et al.: Autologous stem cell transplantation for progressive multiple sclerosis: update of the European group for blood and marrow transplantation autoimmune diseases working party database. Mult. Scler.12,814–823 (2006).
  Medline CASGoogle Scholar
• 108  Shevchenko YL, Novik AA, Kuznetsov AN et al.: High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp. Hematol.36,922–928 (2008).
  Medline CASGoogle Scholar
• 109  Atkins H, Freedman M: Immune ablation followed by autologous hematopoietic stem cell transplantation for the treatment of poor prognosis multiple sclerosis. Methods Mol. Biol.549,231–246 (2009).
  Medline CASGoogle Scholar
• 110  Burt RK, Loh Y, Cohen B et al.: Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing–remitting multiple sclerosis: a Phase I/II study. Lancet Neurol.8,244–253 (2009).
  Medline CASGoogle Scholar
• 111  Rogojan C, Frederiksen JL: Hematopoietic stem cell transplantation in multiple sclerosis. Acta Neurol. Scand.120,371–382 (2009).
  Medline CASGoogle Scholar
• 112  Bonab MM, Yazdanbakhsh S, Lofti J: Does mesenchymal stem cell therapy help multiple sclerosis patients? Report of a pilot study. Iran J. Immunol.4,50–57 (2007).
  MedlineGoogle Scholar
• 113  Liang J, Zhang H, Hua B et al.: Allogeneic mesenchymal stem cells transplantation in treatment of multiple sclerosis. Mult. Scler.15,644–646 (2009).
  Medline CASGoogle Scholar
• 114  Zhang ZX, Guan LX, Zhang K et al.: A combined procedure to deliver autologous mesenchymal stromal cells to patients with traumatic brain injury. Cytotherapy10,134–139 (2008).
  Medline CASGoogle Scholar
• 115  Ting AE, Mays RW, Frey MR et al.: Therapeutic pathways of adult stem cell repair. Crit. Rev. Oncol. Hematol.65,81–93 (2008).
  MedlineGoogle Scholar
• 116  Mays RW, van’t Hof W, Ting AE et al.: Development of adult pluripotent stem cell therapies for ischemic injury and disease. Expert Opin. Biol. Ther.7,173–184 (2007).
  Medline CASGoogle Scholar
• 117  Hare JM, Traverse JH, Henry TD et al.: A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol.54,2277–2286 (2009).
  Medline CASGoogle Scholar
• 118  Newman RE, Yoo D, LeRoux MA et al.: Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm. Allergy Drug Targets8,110–123 (2009).
  Medline CASGoogle Scholar
• 119  Dryden GW: Overview of stem cell therapy for Crohn’s disease. Expert Opin. Biol. Ther.9,841–847 (2009).
  Medline CASGoogle Scholar
• 201  Karussis D: “multiple sclerosis AND stem cell”. ClinicalTrials.gov. A service of the US National Institutes of Health 2010 http://clinicaltrials.gov/ct2/show/NCT00781872
  Google Scholar
• 202  ClinicalTrials.gov. A service of the US National Institutes of Health. “multiple sclerosis AND stem cell”. 1 June 2010 http://clinicaltrials.gov/ct2/results?term=mesenchymal+stem+cells+multiple+sclerosis+
  Google Scholar
• 203  Clinical Trials http://clinicaltrials.gov
  Google Scholar